Although investors are likewise disappointed the F
Post# of 467
"the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult." YEA YEA YEA This is bs but in six months it should be completed. Meanwhile a serious buyer or possible financial partner could emerge IMO to fund or subsidize the clinical research!!
$5-$10+